ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1364

Both Low and High 25(OH)-Vitamin D Levels Increase Adverse Pregnancy Outcomes in Systemic Lupus Erythematosus

Nima Madanchi1, Andrea Fava2, Daniel Goldman3, Larry Magder4, Rebecca Jacobson1 and Michelle Petri3, 1Johns Hopkins University School of Medicine, Baltimore, MD, 2Johns Hopkins University, Baltimore, MD, 3Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, 4University of Maryland, Baltimore, MD

Meeting: ACR Convergence 2023

Keywords: pregnancy, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: (1345–1364) Reproductive Issues in Rheumatic Disorders Poster II

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: We evaluated the role of maternal 25(OH)-vitamin D in adverse pregnancy outcomes in systemic lupus erythematosus (SLE).

Methods: We used a longitudinal cohort that included visits of pregnant patients with assessment of 25(OH)-vitamin D at each visit. Pregnancies were excluded if there was no vitamin D level during pregnancy, if the outcomes of pregnancies were missing (such as data on due date, birth date, gestational age, and complications of pregnancies), or if the pregnancy was terminated. 270 pregnancies were available for the statistical analysis.

Results: We found a U-shape association between the maternal serum 25(OH)-vitamin D level and the combined adverse pregnancy outcomes (P=0.0022), miscarriage (P=0.0048), and preterm delivery (P=0.0003). We also found the same U-shape curve with the low birth weight; but it did not reach statistical significance due to the smaller number of cases. The lowest prevalence of adverse pregnancy outcomes was with 25(OH)-vitamin D in the range of 40-59 ng/dL (Figure 1). The multivariate analysis confirmed the same U-shape association controlling for age, race, and antiphospholipid antibodies (Table 1, Figure 2). The results were similar when we examined the subset in which pre-pregnancy or first trimester BMI were available.

Conclusion: Our study design cannot prove a cause-and-effect relationship. Most of our patients were prescribed vitamin D supplementation (but obviously many did not take it). We recommend monitoring 25(OH)-vitamin D levels during SLE pregnancies. The ideal 25(OH)-vitamin D range was 40-59 ng/dL.

Supporting image 1

Figure 1. Adverse pregnancy outcomes occurrence (%) by mean 25(OH)-vitamin D (ng/dL) during pregnancy.

Supporting image 2

Figure 2. Odds ratios of combined adverse pregnancy outcomes with different mean 25(OH)-vitamin D levels controlling for age, race, and antiphospholipid antibodies.

Supporting image 3

Table 1. Odds ratios of adverse pregnancy outcomes with different mean maternal 25(OH)-vitamin D levels controlling for age, race, and antiphospholipid antibodies.


Disclosures: N. Madanchi: None; A. Fava: Annexon Biosciences, 2, Sanofi, 1; D. Goldman: None; L. Magder: None; R. Jacobson: None; M. Petri: Alexion, 1, Amgen, 1, AnaptysBio, 1, Annexon Bio, 1, Argenx, 1, Arhros-Focus Med/Ed, 6, AstraZeneca, 1, 5, Aurinia, 1, 5, 6, Axdev, 1, Biogen, 1, Boxer Capital, 2, Cabaletto Bio, 2, Caribou Biosciences, 2, CVS Health, 1, Eli Lilly, 1, 5, Emergent Biosolutions, 1, Exagen, 5, Exo Therapeutics, 2, Gilead Biosciences, 2, GlaxoSmithKlein(GSK), 1, 5, 6, Horizon Therapeutics, 2, Idorsia Pharmaceuticals, 2, IQVIA, 1, Janssen, 1, 5, Kira Pharmaceuticals, 2, MedShr, 6, Merck/EMD Serono, 1, Momenta Pharmaceuticals, 2, Nexstone Immunology, 2, Nimbus Lakshmi, 2, Proviant, 2, Sanofi, 2, Sinomab Biosciences, 2, Thermofisher, 5, UCB, 2.

To cite this abstract in AMA style:

Madanchi N, Fava A, Goldman D, Magder L, Jacobson R, Petri M. Both Low and High 25(OH)-Vitamin D Levels Increase Adverse Pregnancy Outcomes in Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/both-low-and-high-25oh-vitamin-d-levels-increase-adverse-pregnancy-outcomes-in-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/both-low-and-high-25oh-vitamin-d-levels-increase-adverse-pregnancy-outcomes-in-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology